9.60
-0.17 (-1.74%)
| Previous Close | 9.77 |
| Open | 9.70 |
| Volume | 841,353 |
| Avg. Volume (3M) | 906,653 |
| Market Cap | 1,322,112,000 |
| Price / Sales | 16.14 |
| Price / Book | 0.820 |
| 52 Weeks Range |
| Operating Margin (TTM) | -9,184.54% |
| Diluted EPS (TTM) | -3.93 |
| Quarterly Revenue Growth (YOY) | -9.80% |
| Total Debt/Equity (MRQ) | 9.09% |
| Current Ratio (MRQ) | 8.94 |
| Operating Cash Flow (TTM) | -466.64 M |
| Levered Free Cash Flow (TTM) | -356.99 M |
| Return on Assets (TTM) | -19.41% |
| Return on Equity (TTM) | -36.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Vir Biotechnology, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.50 |
|
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 11.90% |
| % Held by Institutions | 74.36% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bill & Melinda Gates Foundation | 30 Jun 2024 | 1,559,142 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 110.00 (HC Wainwright & Co., 1,045.83%) | Buy |
| Median | 26.00 (170.83%) | |
| Low | 19.00 (Needham, 97.92%) | Buy |
| Average | 51.67 (438.23%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 7.62 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 20 Nov 2024 | 110.00 (1,045.83%) | Buy | 6.74 |
| 04 Nov 2024 | 110.00 (1,045.83%) | Buy | 9.37 | |
| Needham | 20 Nov 2024 | 19.00 (97.92%) | Buy | 6.74 |
| 01 Nov 2024 | 19.00 (97.92%) | Buy | 9.26 | |
| Barclays | 04 Nov 2024 | 26.00 (170.83%) | Buy | 9.37 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |